Are We Having Fun Yet? Bull Ride Continues

The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...

Hoping for Fireworks

As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is...

Stock Picking Wins This Week

It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

TW's Take: more good news on Oleogel-S10. If the drug is approved, as expected, AMYT is a bargain at current prices. DUBLIN, Ireland, and Boston...

Oregon Trails

Greetings from Ashland, Oregon where my tour of the west coast is ending in fine fashion. The biking here is outstanding, the meals our...

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of...

TW's Take: this is excellent news and positions AMYT for a big move in the second half of 2021. With the Chiasma acquisition, if...

Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of...

TW's Take: continued positive execution for Amryt. We hope to see priority review designation with approval later this year. AMYT should move higher into...

Opportunity Knocks, Amryt Smartly Acquires Chiasma

The pandemic-inspired rally of 2020 was an unexpected surprise for many companies, particularly those in biotech, which soared last year. The access to capital,...

The Beatings Will Continue Until Morale Improves…

Okay, I was early. I admit it. But, unless growth stocks never rally again, biotech in particular, I'm 100% convinced that buying at these...

Amryt Reports Record Q1 2021 Financial and Operating Results

TW's Take: nice to see the guidance increased and it's obvious that the core business is going very well at Amryt, but the key...

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and...

TW's Take: we have been expecting Amryt to make an acquisition and this one is exciting. The prospects for MYCAPSSA are quite strong and...

Amryt Announces the Appointment of Sheila Frame as President Americas

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

Amryt Submits a New Drug Application to the US Food and Drug Administration for...

TW's Take: if approved, Oleogel-S10 is likely to become Amryt's largest drug franchise in very short order. Expect to hear about the acceptance and...

Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS

TW's Take: very encouraging data as a label expansion into FCS would potentially double the addressable market for the drug. Amryt continues to increase...

Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)

TW's Take: further progress as they march towards hopeful approval in EB, which should make Oleogel-S10 their largest product in short order. DUBLIN, Ireland, and...

Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin)...

TW's Take: very positive step forward in broadening the indications for Myalept. Management of Amryt continues to execute well and the stock remains deeply...

Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for...

TW's Take: this further expands the market opportunity for Myalepta, allowing continued growth of this franchise. We remain excited about AMYT as the expected...

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

TW's Take: Amryt's team has continually demonstrated positive progress in expanding their existing franchises.  DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM:...

Blood In The Water

Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...

Amryt (AMYT): A Rare Find in Today’s Market… Growth At A Reasonable Price!

Growing nicely and trading under 20 times 2020 EBITDA, Amryt Pharma (AMYT) has somehow managed to build a global franchise in rare diseases yet...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.